Piedra, A., Arriola Aperribay, E., Recuero-Borau, J., & Majem, M. (2024). First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: Real-world data from a Spanish multicenter study.
Citación estilo ChicagoPiedra, Aida, Edurne Arriola Aperribay, Jordi Recuero-Borau, y Margarita Majem. First-line Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Real-world Data From a Spanish Multicenter Study. 2024.
Cita MLAPiedra, Aida, Edurne Arriola Aperribay, Jordi Recuero-Borau, y Margarita Majem. First-line Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Real-world Data From a Spanish Multicenter Study. 2024.
Precaución: Estas citas no son 100% exactas.